Literature DB >> 16877261

CYP4B1: an enigmatic P450 at the interface between xenobiotic and endobiotic metabolism.

Brian R Baer1, Allan E Rettie.   

Abstract

CYP4B1 belongs to the mammalian CYP4 enzyme family that also includes CYP4A, 4F, 4V, 4X, and 4Z subfamilies. CYP4B1 shares with other CYP4 proteins a capacity to omega-hydroxylate medium-chain fatty acids, which may be related to an endogenous role for the enzyme. CYP4B1 also participates in the metabolism of certain xenobiotics that are protoxic, including valproic acid, 3-methylindole, 4-ipomeanol, 3-methoxy-4-aminoazobenzene, and numerous aromatic amines. Although these compounds have little in common structurally or chemically, their metabolism by CYP4B1 leads to tissue-specific toxicities in several experimental animals. The bioactivation capabilities of rabbit CYP4B1 have also attracted attention in the cancer community and form the basis of a potential therapeutic strategy involving prodrug activation by the CYP4B1 transgene. The metabolic capabilities of human CYP4B1 are less clear due to difficulties in heterologous expression and existence of alternatively spliced products. Also, many CYP4B1 enzymes covalently bind their heme, a posttranslational modification unique to the CYP4 family of P450s, but common to the mammalian peroxidases. These varied characteristics render CYP4B1 an interesting and enigmatic investigational target.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16877261     DOI: 10.1080/03602530600688503

Source DB:  PubMed          Journal:  Drug Metab Rev        ISSN: 0360-2532            Impact factor:   4.518


  34 in total

Review 1.  Structural control of cytochrome P450-catalyzed ω-hydroxylation.

Authors:  Jonathan B Johnston; Hugues Ouellet; Larissa M Podust; Paul R Ortiz de Montellano
Journal:  Arch Biochem Biophys       Date:  2010-08-19       Impact factor: 4.013

2.  Noncovalent interactions dominate dynamic heme distortion in cytochrome P450 4B1.

Authors:  Gareth K Jennings; Mei-Hui Hsu; Lisa S Shock; Eric F Johnson; John C Hackett
Journal:  J Biol Chem       Date:  2018-06-01       Impact factor: 5.157

3.  Ligand characterization of CYP4B1 isoforms modified for high-level expression in Escherichia coli and HepG2 cells.

Authors:  Katharina Roellecke; Vera D Jäger; Veselin H Gyurov; John P Kowalski; Stephanie Mielke; Allan E Rettie; Helmut Hanenberg; Constanze Wiek; Marco Girhard
Journal:  Protein Eng Des Sel       Date:  2017-03-01       Impact factor: 1.650

Review 4.  Ocular cytochrome P450s and transporters: roles in disease and endobiotic and xenobiotic disposition.

Authors:  Mariko Nakano; Catherine M Lockhart; Edward J Kelly; Allan E Rettie
Journal:  Drug Metab Rev       Date:  2014-05-26       Impact factor: 4.518

5.  ω- versus (ω-1)-hydroxylation: Cytochrome P450 4B1 sterics make the call.

Authors:  Emily E Scott
Journal:  J Biol Chem       Date:  2017-03-31       Impact factor: 5.157

6.  Glutamine-451 Confers Sensitivity to Oxidative Inhibition and Heme-Thiolate Sulfenylation of Cytochrome P450 4B1.

Authors:  Matthew E Albertolle; Hyun D Song; Clayton J Wilkey; Jere P Segrest; F Peter Guengerich
Journal:  Chem Res Toxicol       Date:  2019-02-11       Impact factor: 3.739

7.  PPAR/RXR Regulation of Fatty Acid Metabolism and Fatty Acid omega-Hydroxylase (CYP4) Isozymes: Implications for Prevention of Lipotoxicity in Fatty Liver Disease.

Authors:  James P Hardwick; Douglas Osei-Hyiaman; Homer Wiland; Mohamed A Abdelmegeed; Byoung-Joon Song
Journal:  PPAR Res       Date:  2010-03-16       Impact factor: 4.964

8.  Species Differences in Microsomal Oxidation and Glucuronidation of 4-Ipomeanol: Relationship to Target Organ Toxicity.

Authors:  Oliver T Parkinson; Aaron M Teitelbaum; Dale Whittington; Edward J Kelly; Allan E Rettie
Journal:  Drug Metab Dispos       Date:  2016-07-28       Impact factor: 3.922

Review 9.  CYP4 enzymes as potential drug targets: focus on enzyme multiplicity, inducers and inhibitors, and therapeutic modulation of 20-hydroxyeicosatetraenoic acid (20-HETE) synthase and fatty acid ω-hydroxylase activities.

Authors:  Katheryne Z Edson; Allan E Rettie
Journal:  Curr Top Med Chem       Date:  2013       Impact factor: 3.295

10.  Optimized human CYP4B1 in combination with the alkylator prodrug 4-ipomeanol serves as a novel suicide gene system for adoptive T-cell therapies.

Authors:  K Roellecke; E L Virts; R Einholz; K Z Edson; B Altvater; C Rossig; D von Laer; K Scheckenbach; M Wagenmann; D Reinhardt; C M Kramm; A E Rettie; C Wiek; H Hanenberg
Journal:  Gene Ther       Date:  2016-05-19       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.